Aug 6, 2024, 06:07
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting:
“What’s after osimertinib for pts with EGFR+ NSCLC? Researchers are working on options… just released. primary analysis of the phase 2 INSIGHT 2 study of tepotinib, a highly selective MET inhibitor, combined with osimertinib at EGFR Resisters and EGFR Positive UK.”
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer Institute, also added:
“Tepotinib plus osimertinib in EGFR+ and NSCLC with MET amp following progression on first-line osimertinib (INSIGHT 2).
- ORR 50% (56.6% if MET GCN >10; 42.2% if <10)
- mPFS 5.6 mo; mOS 17.8 mo
- On target resistance after combo in 34% pts
Author:
Source: Lungevity Foudation/X and Biagio Ricciuti/X